Haemophilia A management with emicizumab: A survey of haematologists in the United States

1 Mannucci PM, Tuddenham EG. The hemophilias--from royal genes to gene therapy. N Engl J Med 2001; 344(23): 1773–9. doi: 10.1056/nejm200106073442307. MannucciPM TuddenhamEG The hemophilias--from royal genes to gene therapy N Engl J Med 2001 344 23 1773 9 10.1056/nejm200106073442307 11396445 Open DOISearch in Google Scholar

2 Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 (Suppl 6): 1–158. doi: 10.1111/hae.14046. SrivastavaA SantagostinoE DougallA WFH Guidelines for the Management of Hemophilia, 3rd edition Haemophilia 2020 26 Suppl 6 1 158 10.1111/hae.14046 32744769 Open DOISearch in Google Scholar

3 Knobe K, Berntorp E. Haemophilia and joint disease: pathophysiology, evaluation, and management. J Comorb 2011; 1: 51–9. doi: 10.15256/joc.2011.1.2. KnobeK BerntorpE Haemophilia and joint disease: pathophysiology, evaluation, and management J Comorb 2011 1 51 9 10.15256/joc.2011.1.2 555642129090136 Open DOISearch in Google Scholar

4 Oldenburg J, Shima M, Kruse-Jarres R, et al. Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study. Ped Blood Cancer 2020; 67: e28474. doi: 10.1002/pbc.28474. OldenburgJ ShimaM Kruse-JarresR Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study Ped Blood Cancer 2020 67 e28474 10.1002/pbc.28474 32776489 Open DOISearch in Google Scholar

5 Witkop M, Neff A, Buckner TW, et al. Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Haemophilia 2017; 23(4): 556–65. doi: 10.1111/hae.13214. WitkopM NeffA BucknerTW Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study Haemophilia 2017 23 4 556 65 10.1111/hae.13214 28419637 Open DOISearch in Google Scholar

6 Manco-Johnson MJ, Lundin B, Funk S, et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. J Thromb Haemost 2017; 15(11)2115–24. doi: 10.1111/jth.13811. Manco-JohnsonMJ LundinB FunkS Effect of late prophylaxis in hemophilia on joint status: a randomized trial J Thromb Haemost 2017 15 11 2115 24 10.1111/jth.13811 28836341 Open DOISearch in Google Scholar

7 Franchini M. The modern treatment of haemophilia: a narrative review. Blood Transfus 2013; 11(2): 178–82. doi: 10.2450/2012.0166-11. FranchiniM The modern treatment of haemophilia: a narrative review Blood Transfus 2013 11 2 178 82 10.2450/2012.0166-11 362646822790275 Open DOISearch in Google Scholar

8 Lambert T, Benson G, Dolan G, et al. Practical aspects of extended half-life products for the treatment of haemophilia. Ther Adv Hematol 2018; 9(9): 295–308. doi: 10.1177/2040620718796429. LambertT BensonG DolanG Practical aspects of extended half-life products for the treatment of haemophilia Ther Adv Hematol 2018 9 9 295 308 10.1177/2040620718796429 613010030210757 Open DOISearch in Google Scholar

9 Thornburg CD, Duncan NA. Treatment adherence in hemophilia. Patient Prefer Adherence 2017; 11: 1677–86. doi: 10.2147/PPA.S139851. ThornburgCD DuncanNA Treatment adherence in hemophilia Patient Prefer Adherence 2017 11 1677 86 10.2147/PPA.S139851 563006829033555 Open DOISearch in Google Scholar

10 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9(4): 418–35. doi: 10.1046/j.1365-2516.2003.00780.x. WightJ PaisleyS The epidemiology of inhibitors in haemophilia A: a systematic review Haemophilia 2003 9 4 418 35 10.1046/j.1365-2516.2003.00780.x 12828678 Open DOISearch in Google Scholar

11 Shapiro AD, Mitchell IS, Nasr S. The future of bypassing agents for hemophilia with inhibitors in the era of novel agents. J Thromb Haemost 2018; 16(12): 2362–74. doi: 10.1111/jth.14296. ShapiroAD MitchellIS NasrS The future of bypassing agents for hemophilia with inhibitors in the era of novel agents J Thromb Haemost 2018 16 12 2362 74 10.1111/jth.14296 Open DOISearch in Google Scholar

12 Lacroix-Desmazes S, Voorberg J, Lillicrap D, Scott DW, Pratt KP. Tolerating factor VIII: Recent progress. Front Immunol 2019; 10: 2991. doi: 10.3389/fimmu.2019.02991. Lacroix-DesmazesS VoorbergJ LillicrapD ScottDW PrattKP Tolerating factor VIII: Recent progress Front Immunol 2019 10 2991 10.3389/fimmu.2019.02991 Open DOISearch in Google Scholar

13 Carcao M, Escuriola-Ettingshausen C, Santagostino E, et al. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia 2019; 25(4): 676–84. doi: 10.1111/hae.13762. CarcaoM Escuriola-EttingshausenC SantagostinoE The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab Haemophilia 2019 25 4 676 84 10.1111/hae.13762 Open DOISearch in Google Scholar

14 Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18(10): 1570–4. doi: 10.1038/nm.2942. KitazawaT IgawaT SampeiZ A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model Nat Med 2012 18 10 1570 4 10.1038/nm.2942 Open DOISearch in Google Scholar

15 Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377(9): 809–18. doi: 10.1056/NEJMoa1703068. OldenburgJ MahlanguJN KimB Emicizumab prophylaxis in hemophilia A with inhibitors N Engl J Med 2017 377 9 809 18 10.1056/NEJMoa1703068 Open DOISearch in Google Scholar

16 Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379(9): 811–22. doi: 10.1056/NEJMoa1803550. MahlanguJ OldenburgJ Paz-PrielI Emicizumab prophylaxis in patients who have hemophilia A without inhibitors N Engl J Med 2018 379 9 811 22 10.1056/NEJMoa1803550 Open DOISearch in Google Scholar

17 Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 2019; 6(6): E295–E305. doi: 10.1016/S2352-3026(19)30054-7. PipeSW ShimaM LehleM Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study Lancet Haematol 2019 6 6 E295 E305 10.1016/S2352-3026(19)30054-7 Open DOISearch in Google Scholar

18 Young G, Liesner R, Chang T, et al. A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 2019; 134(24): 2127–38. doi: 10.1182/blood.2019001869. YoungG LiesnerR ChangT A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors Blood 2019 134 24 2127 38 10.1182/blood.2019001869 690882831697801 Open DOISearch in Google Scholar

19 US Food and Drug Administration. HEMLIBRA^® (emicizumabkxwh) injection for subcutaneous use, prescribing information [Initial U.S. approval: 2017] 2018. Available from: https://www.gene.com/download/pdf/hemlibra_prescribing.pdf (accessed August 2021). US Food and Drug Administration HEMLIBRA^® (emicizumabkxwh) injection for subcutaneous use, prescribing information [Initial U.S. approval: 2017] 2018 Available from: https://www.gene.com/download/pdf/hemlibra_prescribing.pdf (accessed August 2021). Search in Google Scholar

20 Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost 2017; 117(7): 1348–57. doi: 10.1160/th17-01-0030. KitazawaT EsakiK TachibanaT Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens Thromb Haemost 2017 117 7 1348 57 10.1160/th17-01-0030 629213628451690 Open DOISearch in Google Scholar

21 Callaghan M, Negrier C, Paz-Priel I, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1–4 studies. Blood 2021; 137(16): 2231–42. doi: 10.1182/blood.2020009217. CallaghanM NegrierC Paz-PrielI Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1–4 studies Blood 2021 137 16 2231 42 10.1182/blood.2020009217 806524033512413 Open DOISearch in Google Scholar

22 Schmitt C, Adamkewicz JI, Xu J, et al. Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 study. Thromb Haemost 2021; 121(3): 351–60. doi: 10.1055/s-0040-1717114. SchmittC AdamkewiczJI XuJ Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 study Thromb Haemost 2021 121 3 351 60 10.1055/s-0040-1717114 789554133086400 Open DOISearch in Google Scholar

23 Batsuli G, Zimowski KL, Tickle K, Meeks SL, Sidonio RF, Jr. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis. Haemophilia 2019; 25(5): 789–96. doi: 10.1111/hae.13819. BatsuliG ZimowskiKL TickleK MeeksSL SidonioRFJr Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis Haemophilia 2019 25 5 789 96 10.1111/hae.13819 31373431 Open DOISearch in Google Scholar

24 Batsuli G, Greene A, Meeks SL, Sidonio Jr RF. Emicizumab in tolerized patients with hemophilia A with inhibitors: A single-institution pediatric cohort assessing inhibitor status. Res Pract Thromb Haemost 2021; 5(2): 342–8. doi: 10.1002/rth2.12475. BatsuliG GreeneA MeeksSL SidonioRFJr Emicizumab in tolerized patients with hemophilia A with inhibitors: A single-institution pediatric cohort assessing inhibitor status Res Pract Thromb Haemost 2021 5 2 342 8 10.1002/rth2.12475 793861933733033 Open DOISearch in Google Scholar

25 Oldenburg J, Mahlangu JN, Bujan W, et al. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia 2019; 25(1): 33–44. doi: 10.1111/hae.13618. OldenburgJ MahlanguJN BujanW The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study Haemophilia 2019 25 1 33 44 10.1111/hae.13618 30427582 Open DOISearch in Google Scholar

26 Mancuso ME, Mahlangu J, Sidonio Jr R, et al. Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study. Haemophilia 2020; 26(6): 1009–18. doi: 10.1111/hae.14183. MancusoME MahlanguJ SidonioRJr Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors—Results from the HAVEN 2 study Haemophilia 2020 26 6 1009 18 10.1111/hae.14183 782110833084175 Open DOISearch in Google Scholar

27 Skinner MW, Negrier C, Paz-Priel I, et al. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without Factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia 2021; 27(5): 854–65. doi: 10.1111/hae.14363. SkinnerMW NegrierC Paz-PrielI The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without Factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies Haemophilia 2021 27 5 854 65 10.1111/hae.14363 851888234171159 Open DOISearch in Google Scholar

28 Parnes A, Mahlangu, JN., Pipe, SW., Paz-Priel, I., Lehle, M., Trask, PC., Jiménez-Yuster, V. Patient preference for emicizumab versus prior factor therapy in persons with haemophilia A: results from the HAVEN 3 and HAVEN 4 studies. Haemophilia 2021. doi: 10.1111/hae.14421. ParnesA MahlanguJN. PipeSW. Paz-PrielI. LehleM. TraskPC. Jiménez-YusterV Patient preference for emicizumab versus prior factor therapy in persons with haemophilia A: results from the HAVEN 3 and HAVEN 4 studies Haemophilia 2021 10.1111/hae.14421 34623725 Open DOISearch in Google Scholar

29 Jiménez-Yuste V, Peyvandi F, Klamroth R, et al. Final Analysis of the STASEY Trial: A Single-arm, Multicenter, Open-label, Phase III Clinical Trial Evaluating the Safety and Tolerability of Emicizumab Prophylaxis in Persons with Hemophilia A (PwHA) with Factor (F)VIII Inhibitors [abstract]. Res Pract Thromb Haemost 2021; 5(2). Available from https://abstracts.isth.org/abstract/final-analysis-of-the-stasey-trial-a-single-armmulticenter-open-label-phase-iii-clinical-trial-evaluating-the-safety-and-tolerability-of-emicizumab-prophylaxis-in-persons-with-hemophilia-a-pwha/ (accessed December 2021). Jiménez-YusteV PeyvandiF KlamrothR Final Analysis of the STASEY Trial: A Single-arm, Multicenter, Open-label, Phase III Clinical Trial Evaluating the Safety and Tolerability of Emicizumab Prophylaxis in Persons with Hemophilia A (PwHA) with Factor (F)VIII Inhibitors [abstract] Res Pract Thromb Haemost 2021 5 2 Available from https://abstracts.isth.org/abstract/final-analysis-of-the-stasey-trial-a-single-armmulticenter-open-label-phase-iii-clinical-trial-evaluating-the-safety-and-tolerability-of-emicizumab-prophylaxis-in-persons-with-hemophilia-a-pwha/ (accessed December 2021). 10.1055/s-0041-1728094 Search in Google Scholar

30 McCary I, Guelcher C, Kuhn J, et al. Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures. Haemophilia 2020; 26(4): 631–6. doi: 10.1111/hae.14005. McCaryI GuelcherC KuhnJ Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures Haemophilia 2020 26 4 631 6 10.1111/hae.14005 32311809 Open DOISearch in Google Scholar

31 Barg AA, Livnat T, Budnik I, et al. Emicizumab treatment and monitoring in a paediatric cohort: real-world data. Br J Haematol 2020; 191(2): 282–90. doi: 10.1111/bjh.16964. BargAA LivnatT BudnikI Emicizumab treatment and monitoring in a paediatric cohort: real-world data Br J Haematol 2020 191 2 282 90 10.1111/bjh.16964 32656767 Open DOISearch in Google Scholar

32 Ebbert PT, Xavier F, Seaman CD, Ragni MV. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors. Haemophilia 2020; 26: 41–6. doi: 10.1111/hae.13877. EbbertPT XavierF SeamanCD RagniMV Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors Haemophilia 2020 26 41 6 10.1111/hae.13877 31746522 Open DOISearch in Google Scholar

33 Lenting PJ. Laboratory monitoring of hemophilia A treatments: new challenges. Blood Adv 2020; 4(9): 2111–8. doi: 10.1182/bloodadvances.2019000849. LentingPJ Laboratory monitoring of hemophilia A treatments: new challenges Blood Adv 2020 4 9 2111 8 10.1182/bloodadvances.2019000849 721843432396619 Open DOISearch in Google Scholar

34 Santagostino E, Oldenburg J, Chang T, et al.. Surgical experience from four phase III studies (HAVEN 1–4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors. ISTH; 2019; Melbourne, Australia. Available from https://www.emicizumabinfo.com/content/dam/gene/emicizumabinfo/pdf/presentations/isth-2019-oral-haven-surgeries-santagostino.pdf (accessed December 2021). SantagostinoE OldenburgJ ChangT Surgical experience from four phase III studies (HAVEN 1–4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors ISTH 2019 Melbourne, Australia Available from https://www.emicizumabinfo.com/content/dam/gene/emicizumabinfo/pdf/presentations/isth-2019-oral-haven-surgeries-santagostino.pdf (accessed December 2021). Search in Google Scholar

35 Nuss R, Hedegaard H, Riske B, et al. Medical care for haemophilia. Haemophilia 1998; 4: 1365–2516. doi: 10.1046/j.1365-2516.1998.00196.x. NussR HedegaardH RiskeB Medical care for haemophilia Haemophilia 1998 4 1365 2516 10.1046/j.1365-2516.1998.00196.x 10028302 Open DOISearch in Google Scholar

36 Royal S, Schramm W, Berntorp E, et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002; 8(1): 44–50. doi: 10.1046/j.1365-2516.2002.00581.x. RoyalS SchrammW BerntorpE Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients Haemophilia 2002 8 1 44 50 10.1046/j.1365-2516.2002.00581.x 11886464 Open DOISearch in Google Scholar

37 Garcia-Dasi M, Aznar JA, Jimenez-Yuste V, et al. Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A. Haemophilia 2015; 21(4): 458–64. doi: 10.1111/hae.12618. Garcia-DasiM AznarJA Jimenez-YusteV Adherence to prophylaxis and quality of life in children and adolescents with severe haemophilia A Haemophilia 2015 21 4 458 64 10.1111/hae.12618 25649244 Open DOISearch in Google Scholar

38 Patel AM, Corman SL, Chaplin S, Raimundo K, Sidonio RF. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events. J Med Econ 2019; 22(12): 1328–37. doi: 10.1080/13696998.2019.1669614. PatelAM CormanSL ChaplinS RaimundoK SidonioRF Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events J Med Econ 2019 22 12 1328 37 10.1080/13696998.2019.1669614 31530050 Open DOISearch in Google Scholar

39 Cortesi PA, Castaman G, Trifirò G, et al. Cost-effectiveness and budget impact of emicizumab prophylaxis in haemophilia A patients with inhibitors. Thromb Haemost 2020; 120(02): 216–28. doi: 10.1055/s-0039-3401822. CortesiPA CastamanG TrifiròG Cost-effectiveness and budget impact of emicizumab prophylaxis in haemophilia A patients with inhibitors Thromb Haemost 2020 120 02 216 28 10.1055/s-0039-3401822 31887777 Open DOISearch in Google Scholar

40 Zhou ZY, Raimundo K, Patel AM, et al. Model of short- and long-term outcomes of emicizumab prophylaxis treatment for persons with hemophilia A. J Manag Care Spec Pharm 2020; 26(9): 1109–20. doi: 10.18553/jmcp.2020.19406. ZhouZY RaimundoK PatelAM Model of short- and long-term outcomes of emicizumab prophylaxis treatment for persons with hemophilia A J Manag Care Spec Pharm 2020 26 9 1109 20 10.18553/jmcp.2020.19406 32452276 Open DOISearch in Google Scholar

41 Lin P-C, Liao Y-M, Tsai S-P, Chang T-T. Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low-dose regimens. Pediatr Blood Cancer 2011; 57: 1029–33. doi: 10.1002/pbc.23291. LinP-C LiaoY-M TsaiS-P ChangT-T Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low-dose regimens Pediatr Blood Cancer 2011 57 1029 33 10.1002/pbc.23291 21793191 Open DOISearch in Google Scholar

42 Institute for Clinical and Economic Review; New England Comparative Effectiveness Public Advisory Council. Emicizumab for hemophilia A with inhibitors: effectiveness and value. Final evidence report. [Boston, Mass.]: ICER: April 16, 2018. Available from https://collections.nlm.nih.gov/catalog/nlm:nlmuid-101744955-pdf (accessed December 2021). Institute for Clinical and Economic Review New England Comparative Effectiveness Public Advisory Council Emicizumab for hemophilia A with inhibitors: effectiveness and value. Final evidence report [Boston, Mass.] ICER April 16 2018 Available from https://collections.nlm.nih.gov/catalog/nlm:nlmuid-101744955-pdf (accessed December 2021). Search in Google Scholar

43 Institute for Clinical and Economic Review; New England Comparative Effectiveness Public Advisory Council. Valoctocogene roaparvovec and emicizumab for hemophilia A: effectiveness and value. Final report. [Boston, Mass.]: ICER, November 20; 2020. Available from https://icer.org/wp-content/uploads/2020/10/ICER_Hemophilia-A_Final-Report_112020.pdf (accessed December 2021). Institute for Clinical and Economic Review New England Comparative Effectiveness Public Advisory Council Valoctocogene roaparvovec and emicizumab for hemophilia A: effectiveness and value. Final report [Boston, Mass.] ICER November 20 2020 Available from https://icer.org/wp-content/uploads/2020/10/ICER_Hemophilia-A_Final-Report_112020.pdf (accessed December 2021). Search in Google Scholar

44 Kelley K, CLark B, Brown V, Sitzia J. Good practice in the conduct and reporting of survey research. Int J Qual Health Care 2003; 15(3): 261–6. doi: 10.1093/intqhc/mzg03 KelleyK CLarkB BrownV SitziaJ Good practice in the conduct and reporting of survey research Int J Qual Health Care 2003 15 3 261 6 10.1093/intqhc/mzg03 Open DOISearch in Google Scholar